Edge Therapeutics Reports Positive Early Clinical Experience With EG-1962 to Prevent Serious Complications After Brain Hemorrhage

Published: Jun 27, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW PROVIDENCE, N.J. & DÜSSELDORF, Germany--(BUSINESS WIRE)--Edge Therapeutics announced today positive preliminary results from the first human use of EG-1962, the Company’s novel bioabsorbable nimodipine microparticle formulation for the prevention of delayed cerebral ischemia (DCI), a life-threatening complication of subarachnoid hemorrhage (SAH), typically resulting from a ruptured brain aneurysm or traumatic brain injury. There are approximately 90,000 patients in North America and Europe who are at risk for DCI, most of whom would be candidates for EG-1962.

Help employers find you! Check out all the jobs and post your resume.

Back to news